KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

Recruiting

Phase 2

Phase 3

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor TreatmentKRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

Sponsor:

Kartos Therapeutics, Inc.

Code:

NCT03662126

Conditions

Primary Myelofibrosis (PMF)

Post-Polycythemia Vera MF (Post-PV-MF)

Post-Essential Thrombocythemia MF (Post-ET-MF)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

KRT-232

Best Available Therapy (BAT)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Kartos Therapeutics, Inc. on 2023-04-28.